Indeed, genetic Thp1 ablation or pharmacological inhibition of THP1 protects against obesity, insulin resistance, and fatty liver disease in mice fed an HFD, while increasing the overall metabolic expenditure. Here, GLI2 is linked to obesity due to melanocortin 4 receptor deficiency.